NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label
To determine the Maximum tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of the combination NPI-0052 and Vorinostat
continuously
Yes
Robert Corringham, MD
Study Director
Triphase Research and Development I Corp, Chief Medical Officer
Australia: Department of Health and Ageing Therapeutic Goods Administration
NPI-0052-103
NCT00667082
March 2008
January 2010
Name | Location |
---|